We hope to see you in San Diego.
ClearNote Health will be at AACR 2026. Visit us at Booth #3448 to explore the latest from Virtuoso™, our epigenomic liquid biopsy platform, and connect with the team behind Avantect®, a multiomics early detection test for high mortality cancers.
We'll be presenting new clinical data and discussing BioPharma partnership opportunities. We'd love to find time to connect.
Genome-wide epigenetic insights into cancer biology, response and resistance — all from a simple blood draw.
Learn more →Multiomics liquid biopsy for the early detection of high mortality cancers — providing clarity for elevated risk.
Learn more →Our team will be available throughout the conference for meetings and conversations.
Explore how genome-wide epigenetic profiling from a simple blood draw is transforming cancer biology research and BioPharma drug development.
↓ Download WhitepaperLearn how Avantect® combines multiple biomarker types to deliver superior performance for early detection of high mortality cancers.
↓ Download WhitepaperBook time with our team at Booth #3448 or arrange a dedicated meeting during the conference.
Schedule a MeetingImportant Information
The Virtuoso platform is for research use only. Not for use in diagnostic procedures.
The Avantect Pancreatic and Ovarian Cancer Tests are early detection tests. The tests do not establish a diagnosis of pancreatic or ovarian cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic or ovarian cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic or ovarian cancers will be detected. Some patients with pancreatic or ovarian cancer may have a "Pancreatic/Ovarian Cancer Signal not detected" result. Some patients without pancreatic or ovarian cancer may have a "Pancreatic/Ovarian Cancer Signal detected" result. False-negative and false-positive results are possible. A "Signal not detected" result does not guarantee that no pancreatic or ovarian cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient's blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.
The tests were developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and have not been cleared or approved by the US Food and Drug Administration (FDA).